Immuno-oncology company Affimed made further gains in Tuesday’s market following its 9% jump on Monday.
The firm had just announced a licensing and strategic collaboration agreement with biotech holding company Roivant Sciences to develop and commercialize novel ICE molecules in oncology.
This collaboration grants Roivant a license to the preclinical molecule AFM32 and will also leverage Affimed’s proprietary redirected optimized cell killing (ROCK) platform to generate ICE molecules against targets not included in Affimed’s current pipeline.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze